CHEK1 Antibody

What is CHEK1 and what cellular functions does it regulate?

CHEK1 is a serine/threonine-protein kinase required for checkpoint-mediated cell cycle arrest and DNA repair activation in response to DNA damage or unreplicated DNA. It may also negatively regulate cell cycle progression during unperturbed cell cycles. CHEK1 preserves genomic integrity through multiple mechanisms including recognition of the substrate consensus sequence [R-X-X-S/T] and phosphorylation of key cell cycle regulators like CDC25A, CDC25B, and CDC25C. These modifications create binding sites for 14-3-3 proteins, promoting proteolysis of CDC25A and leading to cell cycle arrest .

What are the common applications for CHEK1 antibodies in research?

CHEK1 antibodies are primarily used in Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA applications. They have demonstrated reactivity with human, mouse, and rat samples, making them versatile tools for cross-species research . Western blotting is particularly useful for detecting CHEK1 in cell lysates, with documented successful detection in various cell lines including U2OS human osteosarcoma cells, MCF-7 human breast cancer cells, CEM human T-lymphoblastoid cells, Balb/3T3 mouse embryonic fibroblast cells, and NRK rat normal kidney cells .

What is the molecular weight of CHEK1 protein and how is it detected on Western blots?

CHEK1 has a calculated molecular weight of approximately 54 kDa, though it is typically observed at 50-55 kDa on Western blots . When conducting Western blots, CHEK1 is commonly detected as a specific band at approximately 57 kDa under reducing conditions . This slight variation between calculated and observed molecular weights is important to consider when interpreting Western blot results.

What are the optimal dilutions for different applications of CHEK1 antibodies?

The optimal dilution of CHEK1 antibodies varies depending on the specific application. For Western blot analysis, a dilution range of 1:500-1:1000 is generally recommended. For immunohistochemistry applications, dilutions between 1:50-1:500 are suitable. For immunofluorescence or immunocytochemistry, a more concentrated dilution of 1:10-1:100 is typically needed . It's important to note that these are general recommendations, and optimal dilutions should be determined by each laboratory for each application to obtain the best results for specific experimental conditions .

How should samples be prepared for optimal CHEK1 detection by Western blot?

For optimal detection of CHEK1 by Western blot, samples should be prepared under reducing conditions using appropriate buffers. Based on validated protocols, PVDF membranes are recommended for protein transfer. The probing procedure typically involves using 1 μg/mL of anti-CHEK1 antibody followed by an appropriate HRP-conjugated secondary antibody, such as Anti-Goat IgG (for goat primary antibodies) . For example, when using Goat Anti-Human/Mouse/Rat CHEK1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1630), an HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017) has been shown to produce specific bands at approximately 57 kDa. Using Immunoblot Buffer Group 1 has also been validated for this application .

What antigen retrieval methods are recommended for CHEK1 immunohistochemistry?

For immunohistochemical detection of CHEK1 in tissue samples, proper antigen retrieval is critical. The recommended method involves using TE buffer at pH 9.0. Alternatively, citrate buffer at pH 6.0 can also be used for antigen retrieval, though this may yield different results depending on the tissue type and fixation conditions . When working with human lung cancer tissue, these antigen retrieval methods have been successfully validated. It's advisable to optimize the antigen retrieval protocol for each specific tissue type and fixation method to ensure optimal staining results.

How can CHEK1 expression be analyzed in relation to cancer prognosis?

CHEK1 expression analysis in relation to cancer prognosis can be performed using several bioinformatics approaches. The PrognoScan database (http://dna00.bio.kyutech.ac.jp/PrognoScan/) provides a platform for evaluating the relationship between CHEK1 expression and patient prognosis across cancer microarray datasets. The Kaplan-Meier plotter (http://kmplot.com/analysis/) can be used to analyze correlations between CHEK1 expression and patient survival in gastric, breast, lung, and ovarian cancers .

Research has demonstrated that differential CHEK1 expression is observed in multiple cancer types, with reduced CHEK1 mRNA expression being associated with unfavorable outcomes in some cancers. When conducting such analyses, statistical significance is typically considered at a Cox p-value < 0.05, and results are displayed using survival curves with hazard ratios (HR) and 95% confidence intervals (CI) .

What experimental approaches can detect CHEK1 modifications in response to DNA damage?

CHEK1 protein undergoes modifications in response to DNA damage, which can be detected through various experimental approaches. Western blotting using phospho-specific antibodies can detect the phosphorylated forms of CHEK1 that appear after DNA damage induction. Researchers can induce DNA damage using agents such as UV radiation, ionizing radiation, or chemical agents like hydroxyurea or camptothecin, then analyze CHEK1 phosphorylation status at specific time points .

Additionally, immunoprecipitation followed by mass spectrometry can provide a comprehensive analysis of CHEK1 post-translational modifications. Functional assays measuring CHEK1 kinase activity toward known substrates (such as CDC25 proteins) can also indicate CHEK1 activation status. When designing such experiments, it's crucial to include appropriate controls and time points to capture the dynamic nature of CHEK1 activation and modification in response to DNA damage .

How can CHEK1 protein-protein interactions be identified and validated?

CHEK1 protein-protein interactions can be identified and validated using a combination of computational and experimental approaches. Computationally, tools like STRING (http://string-db.org/) can predict interactive proteins using CHEK1 as a query. STRING provides a network visualization at a confidence level of 0.90, which can be further analyzed using Cytoscape for network analysis .

Experimentally, co-immunoprecipitation (Co-IP) using CHEK1 antibodies can pull down protein complexes containing CHEK1 and its interacting partners, which can then be identified by mass spectrometry. Proximity ligation assays (PLA) can detect CHEK1 interactions with specific candidate proteins in situ within cells. For validation of direct interactions, in vitro binding assays with purified proteins can be performed. Additionally, functional validation through genetic approaches (such as knockdown or overexpression of interaction partners) can confirm the biological relevance of identified interactions .

How does CHEK1 expression vary across different cancer types?

CHEK1 expression varies significantly across different cancer types, which can be analyzed using the Oncomine database (https://www.oncomine.org/). Analysis of CHEK1 transcription levels shows differential expression patterns when comparing clinical tumor samples to normal tissues. Using strict threshold criteria (p-value < 1 × 10^-8, fold change > 2, and gene rank in the top 1%), researchers can identify the most significant CHEK1 expression alterations across cancer types .

Heat maps from such analyses illustrate the co-expression profiles of CHEK1 in different cancer types. These expression patterns can provide insights into the potential role of CHEK1 in cancer development and progression. For instance, some studies have shown that altered CHEK1 expression is associated with specific cancer types, highlighting its potential as a biomarker or therapeutic target .

What genomic alterations of CHEK1 are observed in cancers?

Genomic alterations of CHEK1 in cancers can be analyzed using the cBioPortal database (http://www.cbioportal.org/). This platform allows for integrative analysis of CHEK1 alterations and clinical characteristics across multiple cancer datasets. Common alterations include amplifications, deep deletions, and missense mutations .

Analysis can include copy number alterations (CNAs) from GISTIC and RNA sequencing data. The primary search parameters typically include various types of alterations, while secondary searches might focus specifically on RNA sequencing data. This comprehensive analysis helps identify patterns of CHEK1 genomic alterations across different cancer types and potentially links these alterations to clinical outcomes .

How can CHEK1 antibodies be used to study the DNA damage response in cancer cells?

CHEK1 antibodies are powerful tools for studying the DNA damage response in cancer cells through multiple approaches. Immunofluorescence using CHEK1 antibodies can visualize the localization and accumulation of CHEK1 at sites of DNA damage within the nucleus. This technique has been validated in cell lines such as HepG2 cells .

Western blotting with total and phospho-specific CHEK1 antibodies can monitor the activation of CHEK1 following DNA damage induction by various genotoxic agents. Immunohistochemistry on cancer tissue samples can assess CHEK1 expression levels and provide insights into its correlation with cancer progression and response to therapy. This approach has been validated in human lung cancer tissue .

For studying CHEK1 function in the DNA damage response, researchers can combine CHEK1 antibody-based detection with CHEK1 inhibitors or genetic knockdown approaches to assess the consequences of CHEK1 inhibition on cancer cell survival, cell cycle progression, and DNA repair capacity. Such combination approaches provide mechanistic insights into how CHEK1 contributes to cancer cell responses to DNA-damaging therapies .

What are common issues encountered in Western blot detection of CHEK1 and how can they be resolved?

When performing Western blots for CHEK1 detection, researchers may encounter several common issues. One frequent problem is non-specific bands, which can be addressed by optimizing antibody dilution (recommended range: 1:500-1:1000) and implementing more stringent washing protocols . If signal is weak or absent, consider using fresh lysates as CHEK1 can be sensitive to degradation, and ensure samples are prepared under reducing conditions as demonstrated in validated protocols .

For inconsistent results between experiments, standardizing lysate preparation is crucial. The choice of lysis buffer can significantly impact CHEK1 detection; Immunoblot Buffer Group 1 has been validated for successful detection . If detecting phosphorylated forms of CHEK1, phosphatase inhibitors must be included in lysis buffers. Additionally, when comparing CHEK1 levels across different cell lines, be aware that the observed molecular weight may range from 50-55 kDa, with specific detection typically around 57 kDa .

How can cross-reactivity issues with CHEK1 antibodies be identified and mitigated?

Cross-reactivity issues with CHEK1 antibodies can significantly impact experimental results. To identify potential cross-reactivity, researchers should first verify antibody specificity using positive and negative controls. Positive controls could include lysates from cells known to express CHEK1, such as U2OS, MCF-7, CEM human cell lines, or Balb/3T3 mouse embryonic fibroblasts and NRK rat normal kidney cells .

For negative controls, CHEK1 knockout or knockdown samples provide the most rigorous validation. To mitigate cross-reactivity, researchers can perform pre-adsorption tests using the immunizing peptide/protein, optimize blocking conditions (typically using 3-5% BSA or non-fat milk), and increase the stringency of wash steps. When working across species, verify the conservation of the epitope sequence, as CHEK1 antibodies like 10362-1-AP have demonstrated reactivity with human, mouse, and rat samples due to conserved epitopes . For applications requiring absolute specificity, monoclonal antibodies may be preferable to polyclonal antibodies.

What considerations are important when using CHEK1 antibodies across different species?

When using CHEK1 antibodies across different species, sequence homology of the target epitope is the primary consideration. While many CHEK1 antibodies show cross-reactivity with human, mouse, and rat samples , the degree of reactivity may vary due to species-specific differences in the CHEK1 protein sequence.

For Western blotting applications, researchers should validate the expected molecular weight in each species, as slight variations may occur. For human, mouse, and rat samples, CHEK1 is typically detected between 50-57 kDa . Species-specific secondary antibodies must be selected to match the host species of the primary antibody (e.g., HRP-conjugated Anti-Goat IgG for goat primary antibodies) .

When performing immunohistochemistry across species, optimization of antigen retrieval methods may be necessary for each species. While TE buffer (pH 9.0) is recommended for human tissues, alternative methods might be more effective for other species . Antibody dilution may also need adjustment when switching between species, with titration experiments recommended to determine optimal conditions for each new species or tissue type.

How can CHEK1 antibodies contribute to research on cancer therapeutic resistance?

CHEK1 antibodies play a crucial role in researching cancer therapeutic resistance by enabling the monitoring of CHEK1 expression and activation status in resistant versus sensitive cancer cells. Using Western blot analysis with CHEK1 antibodies, researchers can compare CHEK1 protein levels across various cancer cell lines with different resistance profiles . Immunohistochemistry on patient-derived tumor samples before and after treatment can reveal changes in CHEK1 expression associated with acquired resistance .

Functionally, CHEK1 antibodies can be used in combination with CHEK1 inhibitors to study how modulation of the DNA damage response pathway affects sensitivity to chemotherapeutic agents. Phospho-specific CHEK1 antibodies are particularly valuable for monitoring CHEK1 activation status in response to DNA-damaging therapies and identifying alterations in this response in resistant cells. Research findings using these approaches have contributed to understanding resistance mechanisms and developing strategies to overcome resistance through combination therapies targeting CHEK1 and related pathways .

What methodological approaches can integrate CHEK1 antibodies with other molecular techniques?

Integrating CHEK1 antibodies with other molecular techniques creates powerful research approaches. Chromatin immunoprecipitation (ChIP) using CHEK1 antibodies, followed by sequencing (ChIP-seq), can identify genomic regions where CHEK1 associates, potentially revealing novel roles beyond its canonical functions . Combining immunoprecipitation with CHEK1 antibodies and mass spectrometry enables comprehensive identification of CHEK1 interacting partners and post-translational modifications in different cellular contexts .

For functional studies, researchers can combine CHEK1 immunodetection with CRISPR-Cas9 genome editing to correlate CHEK1 protein levels with phenotypic changes resulting from genetic modifications. Flow cytometry using phospho-specific CHEK1 antibodies can quantify CHEK1 activation at the single-cell level, revealing heterogeneity within cell populations. Additionally, proximity ligation assays (PLA) with CHEK1 antibodies can visualize and quantify protein-protein interactions in situ. These integrated approaches provide mechanistic insights into CHEK1 function that would not be possible with antibody detection alone .

How can molecular analysis of CHEK1 interactions with microRNAs be studied?

The molecular analysis of CHEK1 interactions with microRNAs represents an emerging research area that combines CHEK1 antibodies with RNA analysis techniques. To study these interactions, researchers can use modified approaches involving Schrodinger suit, MiRTarBase, Discovery Studio Visualizer, PROCHECK, PATCHDOCK, RNAfold, and RNA-composer software as described in previous studies .

The experimental workflow typically begins with bioinformatic prediction of miRNAs that potentially target CHEK1 mRNA using databases like MiRTarBase. Validation of these interactions can be performed using luciferase reporter assays containing the predicted miRNA binding sites from CHEK1 3'UTR. To correlate miRNA levels with CHEK1 protein expression, researchers can transfect cells with miRNA mimics or inhibitors and then use CHEK1 antibodies for Western blot analysis to detect changes in protein levels .

For structural analysis of CHEK1-miRNA interactions, molecular modeling approaches can be employed. RNAfold and RNA-composer software can predict the secondary and tertiary structures of relevant miRNAs, while PATCHDOCK can model the interaction between CHEK1 protein and human argonaute protein complexed with miRNAs. These computational predictions should be validated experimentally, with statistical significance usually considered at p < 0.05 .